Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer
Brennan, Donal J. ; Brändstedt, Jenny LU ; Rexhepaj, Elton ; Foley, Michael ; Ponten, Fredrik ; Uhlen, Mathias ; Gallagher, William M. ; O'Connor, Darran P. ; O'Herlihy, Colm and Jirström, Karin LU
(2010)
In BMC Cancer
10.
- Abstract
- Background: Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer. Methods: HMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA) consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk... (More)
- Background: Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer. Methods: HMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA) consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk of recurrence free survival (RFS). Results: Seventy-two tumours were suitable for analysis. Cytoplasmic HMG-CoAR expression was present in 65% (n = 46) of tumours. No relationship was seen between HMG-CoAR and age, histological subtype, grade, disease stage, estrogen receptor or Ki-67 status. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS (p = 0.012). Multivariate Cox regression analysis revealed that HMG-CoAR expression was an independent predictor of improved RFS (RR = 0.49, 95% CI (0.25-0.93); p = 0.03) when adjusted for established prognostic factors such as residual disease, tumour stage and grade. Conclusion: HMG-CoAR expression is an independent predictor of prolonged RFS in primary ovarian cancer. As HMG-CoAR inhibitors, also known as statins, have demonstrated anti-neoplastic effects in vitro, further studies are required to evaluate HMG-CoAR expression as a surrogate marker of response to statin treatment, especially in conjunction with current chemotherapeutic regimens. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1603277
- author
- Brennan, Donal J.
; Brändstedt, Jenny
LU
; Rexhepaj, Elton
; Foley, Michael
; Ponten, Fredrik
; Uhlen, Mathias
; Gallagher, William M.
; O'Connor, Darran P.
; O'Herlihy, Colm
and Jirström, Karin
LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- BMC Cancer
- volume
- 10
- publisher
- BioMed Central (BMC)
- external identifiers
-
- wos:000276817100001
- scopus:77950540366
- pmid:20359358
- ISSN
- 1471-2407
- DOI
- 10.1186/1471-2407-10-125
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology (Malmö) (013031000), Pathology, (Lund) (013030000)
- id
- a4dfd49b-ad6b-4899-80ff-79b72331a4aa (old id 1603277)
- date added to LUP
- 2016-04-01 13:44:01
- date last changed
- 2024-01-29 02:52:08
@article{a4dfd49b-ad6b-4899-80ff-79b72331a4aa,
abstract = {{Background: Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer. Methods: HMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA) consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk of recurrence free survival (RFS). Results: Seventy-two tumours were suitable for analysis. Cytoplasmic HMG-CoAR expression was present in 65% (n = 46) of tumours. No relationship was seen between HMG-CoAR and age, histological subtype, grade, disease stage, estrogen receptor or Ki-67 status. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS (p = 0.012). Multivariate Cox regression analysis revealed that HMG-CoAR expression was an independent predictor of improved RFS (RR = 0.49, 95% CI (0.25-0.93); p = 0.03) when adjusted for established prognostic factors such as residual disease, tumour stage and grade. Conclusion: HMG-CoAR expression is an independent predictor of prolonged RFS in primary ovarian cancer. As HMG-CoAR inhibitors, also known as statins, have demonstrated anti-neoplastic effects in vitro, further studies are required to evaluate HMG-CoAR expression as a surrogate marker of response to statin treatment, especially in conjunction with current chemotherapeutic regimens.}},
author = {{Brennan, Donal J. and Brändstedt, Jenny and Rexhepaj, Elton and Foley, Michael and Ponten, Fredrik and Uhlen, Mathias and Gallagher, William M. and O'Connor, Darran P. and O'Herlihy, Colm and Jirström, Karin}},
issn = {{1471-2407}},
language = {{eng}},
publisher = {{BioMed Central (BMC)}},
series = {{BMC Cancer}},
title = {{Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer}},
url = {{https://lup.lub.lu.se/search/files/3558893/1627886.pdf}},
doi = {{10.1186/1471-2407-10-125}},
volume = {{10}},
year = {{2010}},
}